fbpx

Atara Biotherapeutics

Pipeline

A Robust Pipeline

Multiple T-Cell Immunotherapy Product Candidates in Clinical Development

Atara Biotherapeutics’s robust, late-stage pipeline features a host of potentially transformative T-cell immunotherapies for cancer, autoimmune and viral diseases. Tab-cel® (tabelecleucel) is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage development for other EBV-associated diseases.

Pipeline

Tab-cel® (tabelecleucel)

Indication Preclinical Phase 1 Phase 2 Phase 3
RR EBV+ PTLD following HCT
  • Tab-cel® (tabelecleucel), Atara’s most advanced T-cell immunotherapy in development, is an investigational treatment for Epstein-Barr
    virus (EBV) associated post-transplant lymphoproliferative disease (EBV+ PTLD), as well as other EBV associated hematologic and
    solid tumors.
  • Tab-cel® is in Phase 3 clinical development for the treatment of EBV+ PTLD following allogeneic hematopoietic cell transplant (HCT)
    after failure of rituximab (NCT03392142, ALLELE study).
RR EBV+ PTLD following SOT
  • Tab-cel® is in Phase 3 clinical development for the treatment of EBV+ PTLD following solid organ transplant (SOT) after failure of rituximab or rituximab and chemotherapy (NCT03394365, ALLELE study).
Nasopharyngeal carcinoma (NPC)
  • Tab-cel® in combination with anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), is in Phase 1b/2 clinical development for patients with platinum-resistant or recurrent EBV-associated NPC (NCT03769467).
EBV+ cancers
  • Phase 2 multi-cohort study planned including EBV+ PTLD with CNS involvement, EBV+ PID/AID LPD, EBV+ LMS and other potential EBV-associated diseases.
Indication Phase
RR EBV+ PTLD following HCTPhase 3
  • Tab-cel® (tabelecleucel), Atara’s most advanced T-cell immunotherapy in development, is an investigational treatment for Epstein-Barr
    virus (EBV) associated post-transplant lymphoproliferative disease (EBV+ PTLD), as well as other EBV associated hematologic and
    solid tumors.
  • Tab-cel® is in Phase 3 clinical development for the treatment of EBV+ PTLD following allogeneic hematopoietic cell transplant (HCT)
    after failure of rituximab (NCT03392142, ALLELE study).
RR EBV+ PTLD following SOTPhase 3
  • Tab-cel® is in Phase 3 clinical development for the treatment of EBV+ PTLD following solid organ transplant (SOT) after failure of rituximab or rituximab and chemotherapy (NCT03394365, ALLELE study).
Nasopharyngeal carcinoma (NPC)Phase 2
  • Tab-cel® in combination with anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), is in Phase 1b/2 clinical development for patients with platinum-resistant or recurrent EBV-associated NPC (NCT03769467).
EBV+ cancersPhase 1
  • Phase 2 multi-cohort study planned including EBV+ PTLD with CNS involvement, EBV+ PID/AID LPD, EBV+ LMS and other potential EBV-associated diseases.
Indication
RR EBV+ PTLD following HCT
Phase
Phase 3
  • Tab-cel® (tabelecleucel), Atara’s most advanced T-cell immunotherapy in development, is an investigational treatment for Epstein-Barr
    virus (EBV) associated post-transplant lymphoproliferative disease (EBV+ PTLD), as well as other EBV associated hematologic and
    solid tumors.
  • Tab-cel® is in Phase 3 clinical development for the treatment of EBV+ PTLD following allogeneic hematopoietic cell transplant (HCT)
    after failure of rituximab (NCT03392142, ALLELE study).
Indication
RR EBV+ PTLD following SOT
Phase
Phase 3
  • Tab-cel® is in Phase 3 clinical development for the treatment of EBV+ PTLD following solid organ transplant (SOT) after failure of rituximab or rituximab and chemotherapy (NCT03394365, ALLELE study).
Indication
Nasopharyngeal carcinoma (NPC)
Phase
Phase 2
  • Tab-cel® in combination with anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), is in Phase 1b/2 clinical development for patients with platinum-resistant or recurrent EBV-associated NPC (NCT03769467).
Indication
EBV+ cancers
Phase
Phase 1
  • Phase 2 multi-cohort study planned including EBV+ PTLD with CNS involvement, EBV+ PID/AID LPD, EBV+ LMS and other potential EBV-associated diseases.

ATA188

Indication Preclinical Phase 1 Phase 2 Phase 3
Progressive MS
  • ATA188, developed using Atara’s T-cell immunotherapy technology from QIMR Berghofer, has the potential to target EBV-infected cells associated with MS pathophysiology.
  • Atara is advancing an ATA188 Phase 1b clinical study in patients with progressive MS at clinical sites in the U.S. and Australia (NCT03283826). To learn more about Atara’s clinical studies, please click here.
Indication Phase
Progressive MSPhase 2
  • ATA188, developed using Atara’s T-cell immunotherapy technology from QIMR Berghofer, has the potential to target EBV-infected cells associated with MS pathophysiology.
  • Atara is advancing an ATA188 Phase 1b clinical study in patients with progressive MS at clinical sites in the U.S. and Australia (NCT03283826). To learn more about Atara’s clinical studies, please click here.
Indication
Progressive MS
Phase
Phase 2
  • ATA188, developed using Atara’s T-cell immunotherapy technology from QIMR Berghofer, has the potential to target EBV-infected cells associated with MS pathophysiology.
  • Atara is advancing an ATA188 Phase 1b clinical study in patients with progressive MS at clinical sites in the U.S. and Australia (NCT03283826). To learn more about Atara’s clinical studies, please click here.

ATA2271/ATA3271

Program/Indication Preclinical Phase 1 Phase 2 Phase 3
ATA2271: Mesothelioma & other solid tumors
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Autologous (ATA2271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
  • MSK investigator-sponsored Phase 1 study (NCT04577326) of a mesothelin-targeted CAR T immunotherapy is ongoing
  • ATA2271 Atara’s CAR T collaboration with MSK will focus on development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies.
ATA3271: Mesothelioma & other solid tumors
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic (ATA3271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
Program/Indication Phase
ATA2271: Mesothelioma & other solid tumorsPhase 1
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Autologous (ATA2271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
  • MSK investigator-sponsored Phase 1 study (NCT04577326) of a mesothelin-targeted CAR T immunotherapy is ongoing
  • ATA2271 Atara’s CAR T collaboration with MSK will focus on development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies.
ATA3271: Mesothelioma & other solid tumorsPreclinical
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic (ATA3271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
Program/Indication
ATA2271: Mesothelioma & other solid tumors
Phase
Phase 1
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Autologous (ATA2271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer
  • MSK investigator-sponsored Phase 1 study (NCT04577326) of a mesothelin-targeted CAR T immunotherapy is ongoing
  • ATA2271 Atara’s CAR T collaboration with MSK will focus on development of a next-generation, mesothelin-targeted CAR T using novel 1XX CAR signaling and PD-1 dominant negative receptor (DNR) checkpoint inhibition technologies.
Program/Indication
ATA3271: Mesothelioma & other solid tumors
Phase
Preclinical
  • Target: Mesothelin
  • Technologies: CAR T PD-1 DNR; Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic (ATA3271)
  • Mesothelin is expressed at high levels on the surface of cells in aggressive solid tumors including mesothelioma, triple-negative breast cancer, esophageal cancer, pancreatic cancer and non-small cell lung cancer

ATA3219

Program/Indication Preclinical Phase 1 Phase 2 Phase 3
ATA3219: B-cell malignancies
  • Target: CD19
  • Technologies: Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic
Program/Indication Phase
ATA3219: B-cell malignanciesPreclinical
  • Target: CD19
  • Technologies: Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic
Program/Indication
ATA3219: B-cell malignancies
Phase
Preclinical
  • Target: CD19
  • Technologies: Novel CAR T 1XX co-stimulation
  • Off-the-shelf, allogeneic

Other Next Gen CAR T Programs

Program/Indication Preclinical Phase 1 Phase 2 Phase 3
ATA2321: Acute myeloid leukemia (AML)
  • Targets: Dual-targeted, undisclosed
  • Technologies: Novel co-stimulation
  • Development expected to start in autologous setting
  • Partnered with Moffitt Cancer Center
ATA2431: B-cell malignancies
  • Targets: Multi-targeted CD19-CD20-CD22
  • Technologies: Novel co-stimulation
  • Development expected to start in autologous setting
  • Partnered with Moffitt Cancer Center
Solid Tumor and Infectious disease CAR T programs
  • Targets: Undisclosed
  • Technologies: Novel CAR T 1XX co-stimulation
  • Partnered with Memorial Sloan Kettering Cancer Center
Program/Indication Phase
ATA2321: Acute myeloid leukemia (AML)Preclinical
  • Targets: Dual-targeted, undisclosed
  • Technologies: Novel co-stimulation
  • Development expected to start in autologous setting
  • Partnered with Moffitt Cancer Center
ATA2431: B-cell malignanciesPreclinical
  • Targets: Multi-targeted CD19-CD20-CD22
  • Technologies: Novel co-stimulation
  • Development expected to start in autologous setting
  • Partnered with Moffitt Cancer Center
Solid Tumor and Infectious disease CAR T programsPreclinical
  • Targets: Undisclosed
  • Technologies: Novel CAR T 1XX co-stimulation
  • Partnered with Memorial Sloan Kettering Cancer Center
Program/Indication
ATA2321: Acute myeloid leukemia (AML)
Phase
Preclinical
  • Targets: Dual-targeted, undisclosed
  • Technologies: Novel co-stimulation
  • Development expected to start in autologous setting
  • Partnered with Moffitt Cancer Center
Program/Indication
ATA2431: B-cell malignancies
Phase
Preclinical
  • Targets: Multi-targeted CD19-CD20-CD22
  • Technologies: Novel co-stimulation
  • Development expected to start in autologous setting
  • Partnered with Moffitt Cancer Center
Program/Indication
Solid Tumor and Infectious disease CAR T programs
Phase
Preclinical
  • Targets: Undisclosed
  • Technologies: Novel CAR T 1XX co-stimulation
  • Partnered with Memorial Sloan Kettering Cancer Center
Tab-cel® (tabelecleucel)

T-cell immunotherapy for EBV-associated ultra-rare diseases

FDA breakthrough designation & EMA PRIME for EBV+ PTLD

View Program
ATA188
EBV T-cell immunotherapy for progressive multiple sclerosis (MS)
View Program
ATA2271/ATA3271
Mesothelin CAR T for solid tumors
View Programs
ATA3219

EBV CD19 CAR T

Off-the-shelf, allogeneic platform clinical proof-of-concept

View Program

Allogeneic Technology

Developing T‑Cells to Treat Specific Conditions

Building upon years of ground-breaking clinical research of collaborators enables us to harness the potential of allogeneic technology and develop unique, off-the-shelf T-cell immunotherapies for the treatment of patients suffering from cancer, certain autoimmune diseases, and serious viral infections.

View Technology
Publications

Developing Investigational T-cell Immunotherapies Based on Clinical Research

A collection of publications and presentations cover various areas of interest.
View Publications
Developing Investigational T-cell Immunotherapies Based on Clinical Research